Biomedical subjects

B Glimelius

Publications and source records attributed to B Glimelius.

328 records · Page 19Linked to original sources

PubMedDate not supplied

Comparative immunohistochemical demonstration of difucosylated carbohydrate antigens and CEA in adenomas and carcinomas of the rectum and rectosigmoid.

The present immunohistochemical investigation reveals that difucosylated carbohydrate antigens (DFCA) are extensively expressed in rectal and rectosigmoid carcinomas while normal mucosa and hyperplastic polyps are mainly negative. The adenomas showed intermediate staining patterns where adenomas with villous structures and moderate-severe dysplasia resembled of carcinomas. CEA was more extensively expressed in both normal, premalignant, and malignant tissue. Thus, DFCA is better than CEA as a discriminator between normal and malignant tissue in the distal large bowel, and may be used in future studies with the intention of advancing our understanding of the neoplastic process and assessing clinical relevance.

Adenoma↗

PubMedDate not supplied

Heterogeneity in proliferation markers in colorectal cancer.

BACKGROUND: The intratumoral heterogeneity in different markers of proliferation, and the immunohistochemical overexpression of the p53 protein-a possible regulator of proliferation-have been investigated to only a minor extent in colorectal cancer. The evaluation of tumour biopsy samples, especially preoperatively, when multiple sampling is not always feasible, must be based upon markers being more or less homogeneously expressed. MATERIALS AND METHODS: Three different DNA-labelling techniques were investigated in multiple biopsy samples (2-10, median 4) from 19 tumours obtained from 18 patients. Anti-bromodeoxyuridine and Ki-67 monoclonal antibodies were used to detect nuclei of proliferating cells in adjacent tumour sections. Adjacent tumour material was analysed by flow cytometry of propidium iodide labelled nuclei. In addition, overexpression of the p53 protein was detected using the monoclonal anti-p53 antibody DO-7 RESULTS: There was considerable intratumoral heterogeneity in the labelling indices. No correlation was found between overexpression of the p53 protein and markers for proliferation, as indicated by observations made using three different methods. In contrast, the staining for p53 protein was either homogeneously positive or negative. CONCLUSIONS: The results indicate that analyses of proliferation in preoperatively obtained tumour biopsies are of limited value for prognostic prediction, or other purposes, in view of the extensive intratumoral heterogeneity shown with three different markers.

Adult↗

PubMedDate not supplied

Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer.

BACKGROUND: We explored the potential value of CA 72-4 in the staging and prognostic prediction of colorectal cancer, as compared to six previously investigated serum tumour markers - CEA, CA 19-9, CA 50, CA 242, TPA, and TPS. MATERIALS AND METHODS: CA 72-4 was analysed using an immunoradiometric assay in serum samples obtained, prior to surgery, from 196 consecutive patients resected between Jan. 1987 and Nov. 1992. RESULTS: CA 72-4 levels increased with progressive tumour stages; a high level correlated with poor prognosis. However, the information obtained from CA 72-4 did not improve the ease of staging, as compared with other tumour markers. Various combinations of CA 72-4 with the other tumour markers did not add any substantial information to the staging process either. The value of the CA 72-4 in prognostic prediction, as shown in the univariate analysis, was limited in the multivariate tumour marker analyses. CONCLUSIONS: CA 72-4 does not improve the staging and prognostic prediction of colorectal cancer, when compared with other serum tumour markers used.

Adult↗

PubMedDate not supplied

Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer.

PURPOSE: To compare immunohistochemical staining using different anti-p53 antibodies, and to evaluate the possible clinical implications of the overexpression of p53 in a series of patients resected for colorectal cancer with a long follow-up. METHODS: Tumor biopsy samples were collected from 294 surgical colorectal cancer specimens, obtained from two series of patients with a median follow-up of 4.5 years. The samples stained with four commercially available anti-p53 antibodies, (mouse monoclonal antibodies 421, 1801, and DO-7; and rabbit polyclonal antibody CM1), were evaluated and compared with cryosections from a subset of 20 biopsies from tumors in various stages and grades, obtained from patients with different outcomes. RESULTS: DO-7 gave a homogeneous nuclear staining, which, when further investigated, turned out to be identical in the formalin-fixed paraffin-embedded and in the frozen specimens. Therefore, DO-7 was found to be suitable for the further analysis of archival or frozen sections from the sample. p53 overexpression was shown in 162 (55%) cases, with a significantly higher proportion having DNA aneuploidy (p<0.01) in left-sided colonic and rectal tumors (p<0.01). p53 staining was not associated with tumor stage, tumor grade, or survival. CONCLUSIONS: A significantly higher proportion of p53 overexpressing tumors are DNA aneuploid, indicating that mutations in the TP53 gene constitute a sign of genetic instability, which might be of importance in malignant transformation. However, we could not find any indication that TP53 mutations, as reflected in the overexpression of p53, constitute a prerequisite for tumor progression in colorectal cancer.

Adult↗